Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Vaxxinity Inc VAXX

Healthcare Biotechnology
Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VAXX)

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

GlobeNewswire March 28, 2024

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire March 27, 2024

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD(TM) 2024

GlobeNewswire March 7, 2024

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

GlobeNewswire February 15, 2024

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

GlobeNewswire February 13, 2024

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

GlobeNewswire January 30, 2024

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

GlobeNewswire January 18, 2024

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

GlobeNewswire November 13, 2023
View More News ››

Opinion & Analysis (NDAQ:VAXX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VAXX)

Be the first to post on this bullboard.

E-Power Resources Inc

E-Power Resources Inc

E-Power Resources Inc. is a Canada-based exploration stage company. The Company is engaged principally in the acquisition ...
View More »